Loading
Lung Cancer Treatments and Mutations / Cancer, Stress, Anesthesia, and Immune Response · Journal article
Advanced Medical Journal · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This single-centre prospective observational study documents a 0.32% incidence of hypersensitivity reactions among 2,160 cancer patients receiving anticancer therapy over 9 weeks, with platinum-based compounds most frequently implicated and all cases responding to corticosteroids and antihistamines. The small absolute number of events (n=7) and lack of a comparator group limit the strength of inference; the study is descriptive and hypothesis-generating rather than definitive.
Prospective observational cohort study. Cancer patients receiving anticancer therapy at Azadi Hematology Oncology Center, Duhok, Iraq; enrolled regardless of cancer type or specific regimen.. Intervention: Anticancer therapy (specific drugs and regimens not enumerated; platinum-based compounds identified as most frequent). n = 2,160. Azadi Hematology Oncology Center, Duhok, Iraq.
Hypersensitivity reaction incidence rate: 0.32% (7 events among 2,160 patients) Male predominance in affected population: 71.4% (5/7) Mean age of affected patients: 56.5 years
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The reported low incidence of hypersensitivity reactions and high rate of successful management with standard agents suggests routine premedication may be protective; however, the small number of events and single-centre setting limit generalizability to other populations and institutions. Platinum-based drugs warrant continued monitoring and preparedness for hypersensitivity management.
Single-centre prospective observational study over 9 weeks with small absolute number of events (n=7) reporting incidence rate; descriptive rather than comparative, and lacks control or mechanistic depth to support generalization.
As stated by the source record.
Quoted from the source exactly as published.
The reported low incidence of hypersensitivity reactions and high rate of successful management with standard agents suggests routine premedication may be protective; however, the small number of events and single-centre setting limit generalizability to other populations and institutions. Platinum-based drugs warrant continued monitoring and preparedness for hypersensitivity management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background and objectives: Hypersensitivity reactions to anticancer drugs pose significant challenges in cancer treatment, possibly leading to treatment interruptions and impacting patient outcomes. Despite their clinical importance, data on the incidence of hypersensitivity reactions in Duhok and Iraq remain scarce. This study aims to determine the incidence rate of hypersensitivity reactions among patients receiving anticancer therapy. Methods: This prospective observational study enrolled 2,160 cancer patients receiving anticancer therapy at Azadi Hematology Oncology Center between January 25 and March 31, 2024, over a 9-week period, during which seven patients developed hypersensitivity reactions. Demographics, treatment regimens, and other data were collected. Statistical analyses were performed to calculate incidence rates and other descriptive statistics. Results: The study reported a hypersensitivity reaction incidence rate of 0.32%. Platinum-based compounds were the most frequently implicated drugs. Symptoms were effectively managed with corticosteroids and antihistamines, resulting in symptom resolution in all cases. The affected population exhibited a male predominance (71.4%, 5/7), with a mean age of 56.5 years. Premedications were administered in 57% of cases (4/7). The most common clinical manifestations were shortness of breath (43%) and pruritus (29%). Fisher's Exact Test was used to compare symptom resolution between patients treated with Oxaliplatin, showing no statistically significant difference in outcomes at p < 0.05. Conclusion: The study highlights a low incidence of hypersensitivity reactions among patients, likely attributed to routine premedication practices, with platinum-based drugs identified as common triggers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.